medigraphic.com
ISSN 2221-2434 (Electronic)

2013, Number 3

<< Back Next >>

Finlay 2013; 3 (3)

Risk Factors Associated with Gastropathies. Trinidad, Sancti Spiritus

Castellanos SK, Lorenzo CFR, Cabrales EJA, Carpio ME, Carrazana RK

Language: Spanish
References: 28
Page: 149-157
PDF size: 184.18 Kb.


ABSTRACT

Background: it is important to identify factors increasing the risk of serious gastrointestinal complications and to determine the actions to take in order to reduce them.
Objective: to identify risk factors associated with gastropathies in patients attending the gastroenterology consultation.
Methods: a study including cases and witness selected out of patients attending the gastroenterology consultation was conducted in a polyclinic in Trinidad, Sancti Spiritus in the year 2008. 104 cases of gastropathies diagnosed by endoscopy and 208 witnesses were studied. The variables analyzed were: age, sex, smoking habit, coffee intake, alcohol consumption and non-steroidal anti-inflammatory drugs. Dichotomous logistic regression was used to control de confounding bias, and subsequently the population attributable risk percent and the dose-response curve were calculated.
Results: the independent risk factors for gastropathies identified were: ingestion of non-steroidal anti-inflammatory drugs (OR 4,50 IC; 2,60 to 7,80 and RAP % 56,75 IC; 37,50 to 71,83) with a significant dose-response curve for daily tablets and months of consumption; smoking habit (OR 2,82 IC; 1,65 to 4,84 and RAP % 38,97 % IC; 18,57 to 57,40) with a significant dose-response curve for daily cigarettes and years of consumption. Non-steroidal anti-inflammatory drugs identified as independent risks were indomethacin, ibuprofen and aspirin. The increase in 1 year of age also represented a risk in this series.
Conclusions: smoking habit in addition to the ingestion of indomethacin, ibuprofen and aspirin were independent risks for gastropathy. Physicians should take into account the effects of these medications to avoid prescribing high doses of them for long periods.


REFERENCES

  1. Misiewicz JJ. The Sydney System: a new classification of gastritis. Introduction. J Gastroenterol Hepatol. 1991 ; 6 (3): 207-8.

  2. Price AB. The Syndey System: histological division. J Gastroenterol Hepatol. 1991 ; 6 (3): 209-22.

  3. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. Am J Surg Pathol. 1996 ; 20 (10): 1161-81.

  4. Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology. 1995 ; 108 (3): 917-24.

  5. Valdivia M. Gastritis y Gastropatías. Rev gastroenterol Perú. 2011 ; 31 (1): 38-48.

  6. Zhang L, Eslick GD, Xia HH, Wu C, Phung N, Talley NJ. Relationship between alcohol consumption and active Helicobacter pylori infection. Alcohol Alcohol. 2010 ; 45 (1): 89-94.

  7. Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006 ; 119 (3): 217-24.

  8. Eurohepygast Study Group. Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study. Gut. 2002 ; 50 (6): 779-85.

  9. Gherasim S, Dranga M. Clinic-epidemiological assesments for establishing the relationship between alcohol consumption and gastritis. Observations in Dorohoi area, Botosani County. Rev Med Chir Soc Med Nat Iasi. 2010 ; 114 (1): 47-51.

  10. Lee YC, Chang CH, Lin JW, Chen HC, Lin MS, Lai MS. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Int. 2012 ; 32 (5): 859-66.

  11. Chang CH, Chen HC, Lin JW, Kuo CW, Shau WY, Lai MS. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiol Drug Saf. 2011 ; 20 (7): 763-71.

  12. Hernández Garcés HR. Manual de endoscopia digestiva superior diagnóstica. La Habana: ECIMED; 2008.

  13. Ministerio de Salud Pública. Formulario Nacional de Medicamentos [Internet]. La Habana: Departamento de Farmacoepidemiología, Dirección Nacional de Medicamentos; 2013. [ cited 26 Sep 2012 ] Available from: http://liscuba.sld.cu/index.php?P=GoTo&ID=2379 &MF=4.

  14. Benichou J. Methods of adjustment for estimating the attributable risk in case-control studies: a review. Stat Med. 1991 ; 10 (11): 1753-73.

  15. Coughlin SS, Benichou J, Weed DL. Estimación del riesgo atribuible en los estudios de casos y controles. Bol Oficina Sanit Panam. 1996 ; 121 (2): 114.

  16. Mantel N. Chi-square tests with one degree of freedom, extensions of the Mantel–Haenszel procedure. J Am Statist Assoc. 1963 ; 58 (303): 690-700.

  17. Maity P, Biswas K, Roy S, Banerjee RK, Bandyopadhyay U. Smoking and the pathogenesis of gastroduodenal ulcer--recent mechanistic update. Mol Cell Biochem. 2003 ; 253 (1-2): 329-38.

  18. Massarrat S. Smoking and Gut. Arch Iran Med. 2008 ; 11 (3): 293-305.

  19. Camargo MC, Piazuelo MB, Mera RM, Fontham ET, Delgado AG, Yepez MC, et al. Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia. Acta Gastroenterol Latinoam. 2007 ; 37 (4): 238-45.

  20. Dall M, Schaffalitzky OB, Møller J, Wildner-Christensen M, Touborg A, Hallas J. Helicobacter pylori and risk of upper gastrointestinal bleeding among users of selective serotonin reuptake inhibitors. Scand J Gastroenterol. 2011 ; 46 (9): 1039-44.

  21. Redéen S, Petersson F, Kechagias S, Mårdh E, Borch K. Natural history of chronic gastritis in a population-based cohort. Scand J Gastroenterol. 2010 ; 45 (5): 540-9.

  22. García LA, Barreales L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007 ; 132 (2): 498-506.

  23. Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J Gastroenterol. 2009 ; 44 Suppl 19: S44-52.

  24. Sokic-Milutinovic A, Krstic M, Rozer-Smolovic B, Alempijevic T. Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4 months follow-up study. Dig Dis Sci. 2010 ; 55 (10): 2887-92.

  25. De Leest HT, Steen KS, Bloemena E, Lems WF, Kuipers EJ, Van de Laar MA, et al. Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial. J Clin Gastroenterol. 2009 ; 43 (2): 140-6.

  26. Ozdil B, Coşar A, Akkız H, Sandıkçı M. Atherosclerosis and acetylsalicylic acid are independent risk factors for hemorrhage in patients with gastric or duodenal ulcer. Anadolu Kardiyol Derg. 2011 ; 11 (1): 53-6.

  27. Hsiang KW, Chen TS, Lin HY, Luo JC, Lu CL, Lin HC, et al. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan. Clin Ther. 2010 ; 32 (7): 1294-303.

  28. Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol. 2009 ; 104 (3): 728-38.




2020     |     www.medigraphic.com